A Mindfulness Approach to UA for Afro-descendants

March 13, 2024 updated by: Brown University

A Mindfulness Approach to Unwinding Anxiety for Afro-descendants

The goal of this clinical trial is to test an app-based mindfulness training program in an Afro-descendant population. The main question[s] it aims to answer are:

  • What changes, if any, does the app need?
  • Is it effective in reducing anxiety among this population?

Participants will be asked to:

  • Use an app-based mindfulness training program daily
  • Complete online surveys at baseline and 2 months post-treatment initiation
  • Complete focused interviews via Zoom at baseline and 2 months post-treatment initiation
  • Complete daily voice diaries via Zoom

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15215
        • University of Pittsburgh Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • GAD-7 ≥ 10
  • Self-identify as Black American and/or Afro-descendant
  • Located in United States or Canada
  • Able to speak English
  • Owns a smartphone

Exclusion Criteria:

  • Any usage of psychotropic medication: not on a stable dosage 6+ weeks
  • As needed (i.e., prn) benzodiazepine use
  • Psychotic disorder (e.g., bipolar disorder, schizophrenia, schizoaffective disorder, psychosis)
  • Cohabiting with a study participant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: App-Delivered Mindfulness Training (MT)
The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Focused interviews
Time Frame: Baseline
In-depth interviews will be conducted to collect participant feedback.
Baseline
Focused interviews
Time Frame: 2 months
In-depth interviews will be conducted to collect participant feedback.
2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in anxiety
Time Frame: Baseline, 2 months
Generalized Anxiety Disorder 7-item will be used to assess anxiety. The GAD-7 is a 7-item questionnaire that uses a 4-point Likert scale where 0 is "Not at all" and 3 is "Nearly every day". Scores can range from 0 to 21 and higher scores indicated a worse outcome.
Baseline, 2 months
Change in worry
Time Frame: Baseline, 2 months
Penn State Worry Questionnaire (PSWQ) will be used to assess worry. The PSWQ is a 16-item questionnaire that uses a 5-point Likert scale where 1 is "Not at all typical of me" and 5 is "Very typical of me". Scores can range from 16 to 80 and higher scores indicate a worse outcome
Baseline, 2 months
Change in non-reactivity
Time Frame: Baseline, 2 months
Non-reactivity subscale from the 15-item Five Facet Mindfulness Questionnaire (FFMQ) will be used to measure changes in emotional reactivity. This subscale is based on responses to 3 questions measured on a 5-point Likert scale where 1 is "Never or rarely" and 5 is "Very often or always true". Scores can range from 3 to 15 and higher scores indicate a better outcome.
Baseline, 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Judson A Brewer, Brown University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 6, 2022

Primary Completion (Actual)

February 5, 2024

Study Completion (Actual)

February 5, 2024

Study Registration Dates

First Submitted

November 4, 2022

First Submitted That Met QC Criteria

May 19, 2023

First Posted (Actual)

May 31, 2023

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 13, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2112003165

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe